- Home
- NCZ vs ACIU Comparison
NCZ vs ACIU Comparison
Compare NCZ & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCZ
- ACIU
- Stock Information
- Founded
- NCZ 2003
- ACIU 2003
- Country
- NCZ United States
- ACIU Switzerland
- Employees
- NCZ N/A
- ACIU N/A
- Industry
- NCZ Finance Companies
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- NCZ Finance
- ACIU Health Care
- Exchange
- NCZ Nasdaq
- ACIU Nasdaq
- Market Cap
- NCZ 225.9M
- ACIU 247.4M
- IPO Year
- NCZ N/A
- ACIU 2016
- Fundamental
- Price
- NCZ $11.75
- ACIU $1.80
- Analyst Decision
- NCZ
- ACIU Strong Buy
- Analyst Count
- NCZ 0
- ACIU 2
- Target Price
- NCZ N/A
- ACIU $12.00
- AVG Volume (30 Days)
- NCZ 533.0K
- ACIU 190.8K
- Earning Date
- NCZ 01-01-0001
- ACIU 03-13-2025
- Dividend Yield
- NCZ 12.16%
- ACIU N/A
- EPS Growth
- NCZ N/A
- ACIU N/A
- EPS
- NCZ N/A
- ACIU N/A
- Revenue
- NCZ N/A
- ACIU $30,136,397.00
- Revenue This Year
- NCZ N/A
- ACIU $120.91
- Revenue Next Year
- NCZ N/A
- ACIU $13.82
- P/E Ratio
- NCZ N/A
- ACIU N/A
- Revenue Growth
- NCZ N/A
- ACIU 84.51
- 52 Week Low
- NCZ $2.50
- ACIU $1.77
- 52 Week High
- NCZ $3.15
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- NCZ 41.50
- ACIU 20.92
- Support Level
- NCZ $11.73
- ACIU $1.95
- Resistance Level
- NCZ $12.00
- ACIU $2.05
- Average True Range (ATR)
- NCZ 0.17
- ACIU 0.12
- MACD
- NCZ 0.02
- ACIU -0.03
- Stochastic Oscillator
- NCZ 56.26
- ACIU 4.10
About NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas and consumable fuels and others.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.